Tealwood Asset Management Inc. Takes Position in ADMA Biologics Inc $ADMA

Tealwood Asset Management Inc. purchased a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 72,087 shares of the biotechnology company’s stock, valued at approximately $1,315,000.

Other large investors have also recently added to or reduced their stakes in the company. Salomon & Ludwin LLC purchased a new stake in ADMA Biologics in the 3rd quarter valued at approximately $25,000. Rothschild Investment LLC increased its position in ADMA Biologics by 373.8% during the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,495 shares during the period. Clearstead Advisors LLC raised its stake in shares of ADMA Biologics by 55.7% during the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after buying an additional 795 shares in the last quarter. iSAM Funds UK Ltd acquired a new stake in shares of ADMA Biologics in the 3rd quarter valued at approximately $34,000. Finally, RiverPark Advisors LLC acquired a new stake in shares of ADMA Biologics in the 3rd quarter valued at approximately $35,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Price Performance

ADMA stock opened at $14.32 on Friday. The firm has a 50 day moving average of $16.33 and a 200-day moving average of $16.64. The company has a market cap of $3.41 billion, a price-to-earnings ratio of 23.87 and a beta of 0.51. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16. ADMA Biologics Inc has a 12-month low of $13.76 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business had revenue of $139.16 million for the quarter, compared to analysts’ expectations of $139.80 million. During the same quarter in the prior year, the firm posted $0.46 EPS. The company’s revenue was up 18.4% compared to the same quarter last year. As a group, equities analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Analyst Ratings Changes

ADMA has been the topic of a number of analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Zacks Research raised ADMA Biologics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 2nd. Finally, Wall Street Zen upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Two analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $32.00.

Insiders Place Their Bets

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the transaction, the chief operating officer owned 466,600 shares of the company’s stock, valued at $7,292,958. The trade was a 2.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Steve Elms acquired 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was acquired at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the transaction, the director directly owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This represents a 0.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 3.50% of the stock is currently owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.